ROLE OF BRCA1 AS A HUMAN PROSTATE SUPPRESSOR GENE

BRCA1 作为人类前列腺抑制基因的作用

• 批准号: 6513444
• 负责人: Eliot M. Rosen
• 金额: $ 20.04万
• 依托单位: LONG ISLAND JEWISH MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-01 至 2003-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6513444
• 关键词: BCL2 gene /protein; DNA repair; androgen receptor; apoptosis; athymic mouse; brca gene; cell cycle; cell growth regulation; cell line; cell proliferation; gene expression; gene targeting; genetic transcription; male; neoplastic growth; oncoprotein p21; prostate; prostate neoplasms; protein degradation; protein structure function

Inherited mutations of the breast and ovary cancer susceptibility gene-1 (BRCA1) confer a significantly increased risk for prostate cancer in male probands; but it is not known if and how BRCA1 regulates the function of prostate cancer cells. Our preliminary studies indicate that wild-type and mutant BRCA1 transgenes differentially modulate multiple phenotypic characteristics of human prostate cancer cell line DU-145, including cell proliferation, in vivo tumor growth, susceptibility to apoptosis, DNA repair activity, and estrogen receptor activity. Some of the phenotypic alterations induced by BRCA1 may be due, in part, to alterations in the expression of key regulatory proteins, including p300, Bcl-2, BRCA2, p21WAF1/CIP1, and Mdm-2. We hypothesize that BRCA1 functions as a prostate tumor suppressor gene by inhibiting cell proliferation, enhancing cellular susceptibility to apoptosis, and reducing cell sensitivity to androgen. In this application, we propose to further investigate the mechanism(s) underlying BRCA1-induced cellular alterations in several different prostate cancer cell lines. We will identify key regions of the BRCA1 molecule involved in modulation of prostate cancer cell proliferation, DNA damage response, expression of important cellular regulatory proteins, and androgen receptor activity. The knowledge from these studies will help to: 1) elucidate mechanisms that may be common to hereditary and sporadic human prostate carcinogenesis; and 2) provide an experimental basis for targetting prostate cancers by enhancing their sensitivity to cytotoxic agents, using BRCA1 gene therapy-related approaches.

乳腺癌和卵巢癌敏感性基因1（BRCA1）的遗传突变赋予了男性概率中前列腺癌的风险显着增加。但是尚不清楚BRCA1是否以及如何调节前列腺癌细胞的功能。 我们的初步研究表明，野生型和突变体BRCA1差异调节人类前列腺癌细胞系DU-145的多种表型特征，包括细胞增殖，体内肿瘤生长，凋亡，DNA修复活性和雌激素受体的易感性。 BRCA1引起的某些表型改变可能部分是由于关键调节蛋白的表达改变，包括P300，BCL-2，BRCA2，P21WAF1/CIP1和MDM-2。 我们假设BRCA1通过抑制细胞增殖，增强细胞对细胞凋亡的敏感性并降低细胞对雄激素的敏感性来充当前列腺肿瘤抑制基因。 在此应用中，我们建议进一步研究几种不同前列腺癌细胞系中BRCA1诱导的细胞改变的机制。 我们将确定参与前列腺癌细胞增殖，DNA损伤反应，重要细胞调节蛋白的表达和雄激素受体活性的BRCA1分子的关键区域。 这些研究的知识将有助于：1）阐明遗传性​​和零星人前列腺癌发生的机制； 2）使用与BRCA1基因治疗相关的方法，通过增强对细胞毒性剂的敏感性来靶向前列腺癌的实验基础。